Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CBSCNYSE:CCMNASDAQ:GRCENASDAQ:PULM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBSCCB Scientific$0.04-8.8%$0.04$0.02▼$0.15$6.58M1.2261,921 shs5,000 shsCCMConcord Medical Services$6.42-3.2%$6.53$3.80▼$12.70$28.76M-0.8417,770 shs2,318 shsGRCEGrace Therapeutics$2.89+1.8%$2.66$1.75▼$4.97$29.31M0.8956,203 shs51,402 shsPULMPulmatrix$8.70+11.4%$6.91$1.78▼$10.40$28.51M1.45133,802 shs20,685 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBSCCB Scientific0.00%+9.38%+30.03%+10.20%-46.24%CCMConcord Medical Services0.00%-6.41%-23.40%+45.02%+10.39%GRCEGrace Therapeutics0.00%-4.38%+1.43%+24.02%+283,999,900.00%PULMPulmatrix0.00%-12.15%+20.52%-6.91%+307.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBSCCB ScientificN/AN/AN/AN/AN/AN/AN/AN/ACCMConcord Medical Services1.6219 of 5 stars0.05.00.00.02.81.70.6GRCEGrace Therapeutics2.3271 of 5 stars3.50.00.00.02.20.81.3PULMPulmatrix0.3999 of 5 stars0.03.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBSCCB Scientific 0.00N/AN/AN/ACCMConcord Medical Services 0.00N/AN/AN/AGRCEGrace Therapeutics 3.00Buy$12.00315.22% UpsidePULMPulmatrix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CBSC, GRCE, CCM, and PULM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBSCCB Scientific$140K47.00N/AN/AN/A∞CCMConcord Medical Services$383.96M0.07N/AN/A$56.67 per share0.11GRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/APULMPulmatrix$1.92M16.53N/AN/A$4.93 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBSCCB ScientificN/AN/A0.00∞N/AN/AN/AN/AN/ACCMConcord Medical Services-$41.93MN/A0.00∞N/AN/AN/AN/AN/AGRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%6/20/2025 (Estimated)PULMPulmatrix-$14.12M-$3.34N/A∞N/A-96.51%-45.97%-30.72%8/11/2025 (Estimated)Latest CBSC, GRCE, CCM, and PULM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23N/AN/AN/AN/AN/A5/15/2025Q1 2025PULMPulmatrixN/A-$0.50N/A-$0.50N/AN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBSCCB ScientificN/AN/AN/AN/AN/ACCMConcord Medical ServicesN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBSCCB ScientificN/AN/AN/ACCMConcord Medical Services1.150.470.46GRCEGrace TherapeuticsN/A6.066.06PULMPulmatrixN/A19.4019.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBSCCB ScientificN/ACCMConcord Medical ServicesN/AGRCEGrace Therapeutics6.08%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipCBSCCB ScientificN/ACCMConcord Medical Services46.50%GRCEGrace Therapeutics13.51%PULMPulmatrix0.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBSCCB Scientific5163.67 millionN/ANot OptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/APULMPulmatrix203.65 million3.63 millionNot OptionableCBSC, GRCE, CCM, and PULM HeadlinesRecent News About These CompaniesPulmatrix Inc.June 2, 2025 | barrons.comPulmatrix set for merger with Cullgen, seeks asset divestmentMay 17, 2025 | uk.investing.comPulmatrix Inc.: Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsMay 15, 2025 | finanznachrichten.dePulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsMay 15, 2025 | prnewswire.comAspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, PulmocideApril 3, 2025 | theglobeandmail.comPulmatrix Reports 2024 Financials and Merger PlansMarch 25, 2025 | tipranks.comPulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | finanznachrichten.dePulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | prnewswire.comPulmatrix revises bylaws, changes voting standardsFebruary 14, 2025 | msn.comCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainJanuary 23, 2025 | finance.yahoo.comHow to Take Advantage of moves in (PULM)January 11, 2025 | news.stocktradersdaily.comWhen the Price of (PULM) Talks, People ListenDecember 11, 2024 | news.stocktradersdaily.comPulmatrix Inc (PULM) Stock: Surpassing Expectations in the MarketNovember 19, 2024 | bovnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 15, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 15, 2024 | bakersfield.comPULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. MergerNovember 14, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 14, 2024 | globenewswire.comPulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed MergerNovember 14, 2024 | finanznachrichten.dePULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to ShareholdersNovember 14, 2024 | joplinglobe.comFramingham-based biopharma company announces merger agreement with San Diego firmNovember 14, 2024 | wbjournal.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBSC, GRCE, CCM, and PULM Company DescriptionsCB Scientific OTCMKTS:CBSC$0.04 0.00 (-8.84%) As of 10:28 AM EasternCB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.Concord Medical Services NYSE:CCM$6.42 -0.22 (-3.24%) Closing price 03:59 PM EasternExtended Trading$6.08 -0.34 (-5.22%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Grace Therapeutics NASDAQ:GRCE$2.89 +0.05 (+1.76%) As of 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Pulmatrix NASDAQ:PULM$8.70 +0.89 (+11.40%) Closing price 04:00 PM EasternExtended Trading$8.75 +0.05 (+0.57%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
